Petros Pharmaceuticals, Inc.

Petros Pharmaceuticals reported a net loss of $0.96 million for the second quarter of 2026 and $1.94 million for the first half of 2026. The company disclosed substantial doubt about its ability to continue as a going concern due to recurring losses and insufficient liquidity. This follows a significant business restructuring in 2025, including the divestment of its Stendra® and VEDs businesses, and a strategic pivot towards developing an Rx-to-OTC switch technology platform. The company also restated prior period financials related to warrant valuations.

Petros Pharmaceuticals announced the mutual separation of Mitchell Arnold from his roles as Vice President of Finance, Principal Accounting Officer, and Principal Financial Officer, effective June 18, 2026. In connection with his departure, Mr. Arnold will receive a severance package including a $38,500 payment, acceleration of 3,000 unvested shares, and up to two months of COBRA premium coverage. Concurrently, the company appointed Robert Weinstein to succeed Mr. Arnold in these positions, effective immediately. Mr. Weinstein brings over thirty years of extensive accounting and finance experience to Petros Pharmaceuticals.

Petros Pharmaceuticals, Inc. announced that its Board of Directors approved the grant of an aggregate of 7,000,000 restricted shares of common stock to its Chairman, President and Chief Commercial Officer, and two directors. The awards, effective June 5, 2026, vest 50% immediately and the remaining 50% on the six-month anniversary, contingent on continued service. These awards were issued outside the company's 2020 Omnibus Incentive Compensation Plan.

Petros Pharmaceuticals reported a net loss of $0.99 million for the first quarter of 2026, significantly reduced from $2.26 million in the prior year, with a basic and diluted EPS of $(0.03). The company's cash and cash equivalents stood at $4.35 million as of March 31, 2026. Management issued a going concern warning, stating that the company lacks sufficient liquidity for the next 12 months, and is exploring various financing strategies while focusing on developing its Rx-to-OTC switch technology platform after discontinuing previous operations.

Petros Pharmaceuticals, Inc. filed its annual report (Form 10-K) for the fiscal year ended December 31, 2025. The company reported an aggregate market value of voting and non-voting common equity held by non-affiliates of $1,437,559 as of June 30, 2025. As of April 15, 2026, there were 42,372,260 shares of common stock outstanding. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.